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Background: Mycobacterium abscessus complex is the second most common organism isolated
from patients with nontuberculous mycobacterial (NTM) lung disease in South Korea. This study
aimed to compare clinical features and treatment outcomes of M. abscessus and Mycobacte-
rium massiliense lung disease.
Methods: We retrospectively identified stored clinical isolates of M. abscessus complex as
either M. abscessus or M. massiliense and reviewed medical records to compare clinical
characteristics and treatment responses. All patients were treated empirically over several
months with multidrug regimens, including a macrolide and one or more parenteral agents.
Results: Of the 249 patient isolates tested, 128 (59 with M. abscessus and 69 with
M. massiliense) met the American Thoracic Society diagnostic criteria for NTM pulmonary
disease, and treatment outcomes were analyzed in 48 patients (26 with M. abscessus andperformed: Asan Medical Center.
ulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center,
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Shortened treatment for M. massiliense lung disease 170722 with M. massiliense). The clinical and radiologic findings were similar between the two
groups. Although the durations of parenteral and total treatment were significantly shorter
in patients with M. massiliense than in those with M. abscessus (4.7 months vs 7.4 months,
P Z .006, and 12.1 months vs 16.3 months, P Z .043), the treatment success rate was
significantly higher in patients with M. massiliense (95.5%) than in M. abscessus cases
(42.3%, P < .001).
Conclusion: Patients with M. massiliense pulmonary infection responded better to this anti-
biotic strategy than those with M. abscessus infection. A shortened duration of treatment
may be sufficient for M. massiliense pulmonary infection.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Nontuberculous mycobacteria (NTM), which includes
rapidly growing mycobacteria (RGM), are ubiquitous or-
ganisms increasingly emerging as important human patho-
gens [1,2]. In Korea, Mycobacterium abscessus complex is
the most frequent RGM causing chronic lung disease [3]. M.
abscessus complex is also notable for its resistance to first-
line anti-tuberculosis drug and treatment difficulty with
poor clinical outcomes [4]. In 2007, the American Thoracic
Society (ATS) recommended periodic administration of
multidrug therapy for affected cases, including a macrolide
and one or more parenteral agents (amikacin, cefoxitin, or
imipenem), or a combination of parenteral agents, over
several (2e4) months [1]. However, these treatments are
quite difficult and there are no established optimal treat-
ment regimens showing good long-term outcomes [5]. M.
abscessus complex is the second most commonly isolated
NTM in Korea. In addition, the prevalence of chronic lung
disease due to M. abscessus complex is increasing in South
Korea [3].
For a long time, M. abscessus, Mycobacterium massi-
liense, and Mycobacterium bolletii had been thought to
represent subgroups of a single species because of an
overlap in biochemical and genetic properties. However,
in 2006, two of these RGM species, M. massiliense and M.
bolletii, have been separated from M. abscessus based on
<97% rpoB gene sequence homology [6]. Recently, in
2011, M. massiliense and M. bolletii were united and
reclassified as a single subspecies within M. abscessus: M.
abscessus subsp. bolletii comb. nov [7]. However, the
placement of M. massiliense within the boundary of M.
abscessus subsp. bolletii remains highly controversial
with regard to clinical aspects. Therefore, we used the
old taxonomy instead of new one. In Korea, M. abscessus
and M. massiliense infections present in almost equal
numbers, whereas M. bolletii is very rare. Two recent
studies have reported that patients with M. massiliense
infections had significantly better treatment responses to
combination antibiotic therapy than those with M.
abscessus infections [8,9]. The aim of the present
study was to evaluate the differences in the clinical
characteristics and treatment outcomes between M.
massiliense and M. abscessus pulmonary infections in a
Korean population.Materials and methods
Study population
Patients who were diagnosed with M. abscessus complex
lung disease and who were treated based on 2007 ATS
guidelines from January 2006 to June 2012 at the Asan
Medical Center (Seoul, South Korea) were retrospectively
evaluated. Clinical, radiological, and microbiological char-
acteristics, management, and treatment outcome data
were retrospectively collected from medical records. Initial
standard posteroanterior and lateral chest radiographs
(CXRs) and computed tomography (CT) results were rean-
alyzed based on seven categories: bronchiectasis, bron-
chiolitis, cavities, consolidation, bilateral involvement,
multilobar involvement (3 lobes with abnormalities), and
type of disease (nodular bronchiectatic form, upper lobe
cavitary form, and unclassifiable form). This study was
approved by the Institutional Review Board of the Asan
Medical Center. Informed consent was waived because of
the retrospective nature of the study.Microbiological examination
Acid-fast bacilli (AFB) were cultured in both solid Ogawa
medium (Korean Institute of Tuberculosis, Osong, Korea)
and a liquid MGIT system (Becton Dickinson, Sparks, MD).
Cultured isolates were identified as Mycobacterium tuber-
culosis or NTM using the Duplex PCR test (Seegene Inc.,
Seoul, Korea). NTM species were identified using a poly-
merase chain reaction-restriction fragment length poly-
morphism method, based on the rpoB gene [10]. Further
differentiation among M. abscessus complex members was
performed at the Department of Microbiology, Seoul Na-
tional University College of Medicine (Seoul, Korea) using
sequence analysis targeting the rpoB and hsp65 genes [8].
The in vitro antimicrobial susceptibility of M. abscessus was
tested using a commercial kit (Sensititre; TREK Diagnostic
Systems, Cleveland, OH) and interpreted according to the
Clinical and Laboratory Standards Institute (CLSI) document
M24-A of 2003 [11].
We defined “persistent culture conversion” as the first
negative sputum culture with at least one subsequent
negative culture and no subsequent positive results during
1708 J. Lyu et al.treatment, and “initial sputum culture conversion” as the
first negative sputum culture with at least one subsequent
negative culture regardless of reversion thereafter. Micro-
biological relapse was defined as two consecutive positive
cultures after sputum conversion [12].
Patient management
As described in a previous report [13], all of our study pa-
tients were treated according to ATS guidelines. The
treatment regimen comprised a multidrug therapy,
including a macrolide and one or more parenteral agents
over 2e4 months. At treatment initiation, information on
the differentiation between M. abscessus and M. massi-
liense was unavailable and only became so in 2011. The
expected durations of cefoxitin/imipenem treatment,
amikacin treatment, and total treatment were 2e4
months, 6 months, and more than 12 months (1 year after
culture conversion), respectively. However, the decision on
the actual treatment duration was made by the attending
physicians, considering the timing of culture conversion,
drug adverse reactions, concomitant diseases, and so on. In
the case of localized disease, surgical treatment was also
considered.
Assessment of treatment outcomes
Treatment outcomes were evaluated until December 31st,
2013. Treatment outcomes were classified as treatment
success, failure, or default. “Treatment success” was
defined to satisfy all of the following criteria: (1) culture
conversion; (2) clinical improvement; (3) minimum duration
of medication at least 6 months; and (4) treatment
completion to the satisfaction of the attending physician.
The time of conversion was defined as the date of the first
negative culture. If the patient could not expectorate
sputum, it was considered that the sputum had converted
to negative. Clinical improvement was defined as an
improvement in clinical symptoms and a decrease or at
least no change in abnormal shadows on chest radiography
or CT scanning. “Failure” was defined as failure to convertFigure 1 Flow diagram of progressto negative sputum culture after treatment for 6 months or
more and an absence of clinical improvement. “Default”
was defined as interruption of treatment for more than 2
consecutive months. “Relapse” was defined as more than
two consecutive positive cultures after treatment comple-
tion. Patients were examined every 2 weeks for 1 month
and then every 1e2 months for the whole duration of
treatment. Sputum AFB smear/culture and chest radiog-
raphy were requested at each visit. After completion of
treatment, patients were followed up clinically and radio-
logically, and bacteriologically if necessary, every 3e6
months [13].
Data analysis
Results are presented as the mean  standard deviation
(SDs). Differences between categorical variables were
assessed using the chi-squared test or Fisher’s exact test, as
appropriate, and differences between continuous variables
were explored using the unpaired t-test. A P value <.05 was
considered statistically significant. Multivariate analysis
was not performed because of the small sample size. All
statistical analyses were performed using SPSS Version 13
for Windows (SPSS Inc., Chicago, IL) and Microsoft Excel 7.0
(Microsoft Corporation, Redmond, WA).
Results
Baseline clinical characteristics
From January 2006 to June 2012, M. abscessus complex
clinical isolates from 249 patients were kept in storage,
allowing sequence analysis. Sequence analysis of the rpoB
and hsp65 genes of these 249 clinical isolates of M.
abscessus complex resulted in the identification of 113 M.
abscessus isolates (45.4%) and 136 M. massiliense isolates
(54.6%). There were no M. bolletii isolates. Of the isolates
from 249 patients, 128 patients (59 with M. abscessus and
69 with M. massiliense) met the diagnostic criteria for NTM
pulmonary disease according to ATS guidelines (Fig. 1). Ofthrough the phases of this study.
Table 1 Baseline clinical characteristics of the 48 patients with Mycobacterium abscessus complex pulmonary disease.
Patient characteristics M. abscessus
n Z 26 (%)
M. massiliense
n Z 22 (%)
Total
n Z 48 (%)
P value
Age, years, mean  SD 56.8  11.1 58.8  12.4 57.7  11.6 .558
Gender, female 17 (65.4) 18 (81.8) 35 (72.9) .202
BMI, kg/m2, mean  SD 20.4  2.7 20.0  3.0 20.2  2.8 .641
Previous pulmonary tuberculosis 12 (46.2) 9 (40.9) 21 (43.8) .715
Never smoker 21 (80.8) 20 (90.9) 41 (85.4) .429
FVC, % predicted, mean  SD 75.5  16.3 79.9  16.5 77.3  16.3 .424
FEV1, % predicted, mean  SD 73.6  19.3 83.6  18.4 77.7  19.3 .125
AFB smear positive 22 (84.6) 17 (77.3) 39 (81.3) .713
Symptoms
Cough 17 (65.4) 18 (81.8) 35 (72.9) .202
Sputum 22 (84.6) 17 (77.3) 39 (81.3) .713
Hemoptysis 10 (38.5) 13 (59.1) 23 (47.9) .154
Dyspnea 8 (30.8) 11 (50.0) 19 (39.6) .175
Easy fatigability 11 (42.3) 5 (22.7) 16 (33.3) .152
Abbreviations: SD, standard deviation; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; AFB,
acid-fast bacilli.
Shortened treatment for M. massiliense lung disease 1709the 128 patients who met our study criteria, 26 with M.
abscessus and 22 with M. massiliense infections received
parenteral antimicrobial treatment. We compared clinical
characteristics and treatment outcomes between the 26
patients with M. abscessus and 22 patients with M. massi-
liense infections. Table 1 summarizes the baseline charac-
teristics of the patients. No significant differences were
found between the M. abscessus and M. massiliense groups
in any of the baseline characteristics, including de-
mographic data and respiratory symptoms. The radio-
graphic findings were generally similar in both groups.
Patients with M. abscessus had nearly twice the frequency
of cavitation but the difference was not statistically sig-
nificant (Table 2).
Drug susceptibility tests (DSTs) were performed on 38
isolates of M. abscessus complex recovered from 48 pa-
tients (Table 3). M. abscessus was susceptible to amikacin
(100%), cefoxitin (95.5%), and clarithromycin (95.5%), and
M. massiliense was susceptible to amikacin (100%), cefox-
itin (81.3%), and clarithromycin (100%) without statistical
significance.Table 2 Baseline chest CT findings of the 48 study patients wit
Chest CT findings M. abscessus
n Z 26 (%)
Bronchiectasis 25 (96.2)
Bronchiolitis 25 (96.2)
Cavities 9 (34.6)
Consolidation 16 (61.5)
Bilateral involvement 20 (76.9)
Multilobar (3 lobes) 21 (80.8)
Type of disease
Nodular bronchiectatic form 17 (65.4)
Upper lobe cavitary form 8 (30.8)
Unclassifiable form 1 (3.8)
Abbreviations: CT, computed tomography.Antimicrobial treatment
As described in a previous report [13], all patients were
treated according to ATS guidelines [1], and the treatment
regimen was individualized based on patient tolerance
(Table 4). The multidrug therapy consisted of a macrolide
and one or more parenteral agents (amikacin and/or
cefoxitin/imipenem) over 2e4 months. In all patients,
clarithromycin (1000 mg/day) was selected as the first
choice; in six patients, clarithromycin was replaced by
azithromycin (250 mg/day) because of adverse reactions,
mainly gastrointestinal problems. The durations of paren-
teral and total treatment were significantly shorter in the
patients with M. massiliense than in those with M. absces-
sus (4.7 months and 7.4 months, PZ .006, and 12.1 months
and 16.3 months, P Z .043, respectively).
Surgical treatment
Nine of our patients (18.8%), eight with M. abscessus
infection and one with M. massiliense infection, underwenth Mycobacterium abscessus complex pulmonary disease.
M. massiliense
n Z 22 (%)
Total
n Z 48 (%)
P value
18 (81.8) 43 (89.6) .165
20 (90.9) 45 (93.8) .587
4 (18.2) 13 (27.1) .202
11 (50.0) 27 (56.3) .422
16 (72.7) 36 (75.0) .738
17 (77.3) 38 (79.2) .766
18 (81.8) 35 (72.9)
3 (13.6) 11 (22.9) .371
1 (4.5) 2 (4.2)
Table 3 In Vitro susceptibility test results of 22 Mycobacterium abscessus and 16 Mycobacterium massiliense isolates from the
study cohort.
Drug Species No. (%) of isolates P value
Susceptible Intermediate Resistant
Clarithromycin M. abscessus 21 (95.5) 0 1 (4.5) 1.00
M. massiliense 16 (100.0) 0 0
Amikacin M. abscessus 20 (90.9) 2 (9.1) 0 1.00
M. massiliense 14 (87.5) 2 (12.5) 0
Cefoxitin M. abscessus 2 (9.1) 19 (86.4) 1 (4.5) .326
M. massiliense 2 (12.5) 11 (68.8) 3 (18.8)
Ciprofloxacin M. abscessus 2 (9.1) 4 (18.2) 16 (72.7) .387
M. massiliense 0 (0.0) 2 (12.5) 14 (87.5)
Linezolid M. abscessus 15 (68.2) 3 (13.6) 4 (18.2) .438
M. massiliense 11 (68.8) 4 (25.0) 1 (6.3)
Drugs and breakpoints are listed according to the recommendations contained in the NCCLS document M24-A2.
1710 J. Lyu et al.adjunctive surgical resection during medical treatment,
and seven of these nine patients (77.8%) successfully
completed treatment. The most common indication for
surgery was culture conversion failure (8 patients, 88.9%).
Two patients had two surgical procedures, and a total of
seven lobectomies, two pneumonectomies, one segmen-
tectomy, and one wedge resection were performed. Post-
operative complications occurred in two patients (22.2%),
including postoperative pneumonia in one and broncho-
pleural fistula and wound dehiscence in the other. All pa-
tients continued antibiotic therapy postoperatively.
Treatment outcomes
Among our 128 included patients, 50 had been observed
without treatment and 30 were lost to follow-up (Fig. 1). A
final cohort of 48 patients was therefore included in our
treatment outcome analysis (Table 5). Both symptomatic
and radiographic improvement rates were lower for pa-
tients with M. abscessus infection than for those with M.
massiliense infection (50.0% vs 81.8%, P Z .022, and 34.6%
vs 72.7%, P Z .008, respectively). Cultures persistently
converted to negative in 32 patients (66.7%) at a mean
duration of 114  185 days. The persistent culture con-
version rate was lower in patients with M. abscessusTable 4 Treatment modalities for Mycobacterium abscessus an
Treatment modality M.ab
n Z
Surgical treatment 8 (3
Medical treatment
Macrolide/amikacin/cefoxitin 10 (
Macrolide/amikacin/imipenem 8 (3
Macrolide/amikacin 4 (1
Macrolide/cefoxitin 2 (7
Macrolide/imipenem 2 (7
Clarithromycin/azithromycin 23/3
Duration of parenteral treatment, month, mean  SD 7.4
Total duration of treatment, month, mean  SD 16.3
Abbreviations: SD, standard deviation.infection than in those with M. massiliense infection (42.3%
and 95.5%, respectively; PZ .029) and the time to negative
culture conversion was shorter in the M. massiliense group
(42  13 days) than in the M. abscessus group (239  78
days) (P Z .030). Initial culture conversion and then
reversion was observed in 8 (30.8%) and 1 (4.5%) patients,
respectively.
The treatment success, failure, and default rates were
42.3% (11/26), 42.3% (11/26), and 15.4% (4/26), in M.
abscessus group, and 95.5% (21/22), 4.5% (1/22), and 0% (0/
22), in M. massiliense group, respectively. The treatment
success rate was higher in patients with M. massiliense
infection than in those with M. abscessus infection (95.5%
[21/22] vs 42.3% [11/26], P < .001). The rate of successful
treatment completion without relapse was also higher in
patients with M. massiliense disease than in patients with
M. abscessus disease (77.3% [17/22] vs 30.8% [8/26],
P < .05) during the follow-up period (mean 1087  848 days,
range 52e2756 days).Discussion
Since M. massiliense was distinguished as a separate or-
ganism from M. abscessus, only two studies have comparedd Mycobacterium massiliense lung disease.
scessus
26 (%)
M.massiliense
n Z 22 (%)
Total
n Z 48 (%)
P value
0.8) 1 (4.5) 9 (18.8) .024
38.5) 9 (40.9) 19 (39.6)
0.8) 4 (18.2) 12 (25.0)
5.4) 7 (31.8) 11 (22.9)
.7) 2 (9.1) 4 (8.3)
.7) 0 2 (4.2)
19/3 42/6
 3.9 4.7  2.5 6.0  3.6 .006
 11.6 12.1  4.4 14.3  9.4 .043
Table 5 Treatment responses of the study patients with Mycobacterium abscessus and Mycobacterium massiliense lung
disease.
Treatment response M.abscessus
n Z 26 (%)
M.massiliense
n Z 22 (%)
Total
n Z 48 (%)
P value
Symptomatic response .022
Improved 13 (50.0) 18 (81.8) 31 (64.6)
Unchanged 13 (50.0) 4 (18.2) 17 (35.4)
Radiographic response .008
Improved 9 (34.6) 16 (72.7) 25 (52.1)
Unchanged 9 (34.6) 6 (27.3) 15 (31.3)
Worsened 8 (30.8) 0 (0.0) 8 (16.6)
Microbiologic response .029
Persistent culture conversion 11 (42.3) 21 (95.5) 32 (66.7)
Initial culture conversion and reversion 8 (30.8) 1 (4.5) 9 (18.8)
Failure of culture conversion 7 (26.9) 0 (0.0) 7 (14.6)
Time to culture conversion, day, mean  SD 239  78 42  13 114  185 .030
Successful treatment completion 11 (42.3) 21 (95.5) 32 (66.7) .000
Relapse 3/11 (27.3) 4/21 (19.0) 7/32 (21.9) .667
Time to relapse, day, mean  SD 131  94 491  259 336  271 .074
Abbreviations: SD, standard deviation.
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abscessus and M. massiliense infections [8,9]. Our present
data reconfirmed that patients with M. massiliense in-
fections showed more a favorable response to the same
combination antibiotic therapy than those with M. absces-
sus infections. However, the previous report did not present
information that would support shorter treatment duration
for M. massiliense lung disease than for M. abscessus lung
disease. Moreover, our present study demonstrated a
significantly shorter duration of treatment and time to
negative culture conversion in patients with M. massiliense
than in cases with M. abscessus. From a clinical point of
view, these data suggest that the treatment guidelines for
infected patients may be differentially developed based on
the causative organisms: M. massiliense vs M. abscessus. To
the best of our knowledge, this is the first study to focus
primarily on the treatment duration of the species differ-
entiation between M. abscessus and M. massiliense.
Traditionally, M. abscessus lung disease has been asso-
ciated with substantial morbidity and mortality. Hence, it
has been regarded as a chronic incurable infection with
current combination antibiotic treatments [1,2]. Moreover,
the ATS guidelines comment that the goal of 12 months of
negative sputum cultures while on therapy may be
reasonable. However, after completion of intravenous drug
therapy, oral therapy is extremely limited, and could
include a macrolide, linezolid, or possibly other agents.
Nevertheless, the effectiveness of macrolide is limited
because of inducible resistance, and it is unclear if there is
any reliable effective oral drug [1]. Therefore, the optimal
regimen and duration of treatment for M. abscessus com-
plex lung diseases after completion of intravenous drug
remain unclear.
Our present study findings reconfirmed that the favor-
able microbiological response rate is higher in patients with
M. massiliense infection than in M. abscessus cases. Our
current data have demonstrated a significantly shorter
treatment duration and time to negative culture conversionin patients with M. massiliense than in those with M.
abscessus. Moreover, in more than half of our M. massi-
liense patients (n Z 13), negative culture conversion
occurred within 1 month of treatment initiation. This in-
dicates that treatment of M. massiliense lung disease may
be easier and can be of shorter duration than that of M.
abscessus. In our hospital, the differentiation of these two
bacterial subtypes was not part of routine practice until
2011. Accordingly, we treated the affected patients until
2012 without knowing the subtype of M. abscessus complex.
Hence, the significantly shorter duration of treatment in
patients with M. massiliense disease could be because the
clinicians decided to complete the treatment earlier based
on a favorable treatment response and rapid culture con-
version. From a clinical stand point, our present data may
suggest the possibility of shortening the treatment duration
for M. massiliense infection. Additional studies are needed
to access the effectiveness of a shortened treatment
duration for M. massiliense lung disease.
Inducible resistance to clarithromycin may explain the
poor treatment outcomes seen in patients with M. absces-
sus lung disease. Koh et al. [8] reported that all M.
abscessus isolates showed inducible resistance to clari-
thromycin, unlike M. massiliense isolates. These authors
found that the induction of the erythromycin ribosome
methyltransferase gene (erm [41]) led to macrolide resis-
tance in M. abscessus infection but not in M. massiliense
infection. Such a difference in inducible resistance could
explain the better treatment outcomes of M. massiliense
lung disease cases. In our present study, we did not test for
inducible resistance to clarithromycin and further in-
vestigations are needed to address this issue.
Azithromycin may be a better option for treating M.
abscessus infection than clarithromycin, whereas both
macrolides appear to be reasonable options for treating M.
massiliense infection. A recent report compared the ac-
tivity of clarithromycin and azithromycin in experimental
models, and found that the azithromycin treatment showed
1712 J. Lyu et al.greater efficacy than clarithromycin against M. abscessus
infection because clarithromycin is a more potent inducer
of erm (41) expression than azithromycin in M. abscessus
[14]. In our present study, clarithromycin was initially
selected as the first treatment choice, and only six patients
received azithromycin instead of clarithromycin because of
an adverse reaction. Therefore, it was impossible to
compare the treatment responses of the clarithromycin-
treated and azithromycin-treated groups in this study.
Prospective controlled trials are needed to assess the
effectiveness of azithromycin instead of clarithromycin in
patients with M. abscessus infection.
Our present report has several limitations inherent to its
retrospective and single-center study design. The number
of enrolled patients was small and the definition of treat-
ment outcomes were arbitrarily chosen because no stan-
dardized definitions are yet available. Moreover, the
follow-up duration after treatment completion was insuf-
ficient to determine relapse rate. We could however
reconfirm from our present data that patients in Korea with
a M. massiliense infection showed more successful treat-
ment outcomes than those with M. abscessus infections.
The treatment duration was also significantly shorter in
patients with M. massiliense infection than in those with M.
abscessus infection. Future studies focusing on optimal
treatment durations are needed for patients infected with
these bacteria.
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